Introduction.
This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information..
Reasons to Purchase.
*Benchmark Bristol-Myers Squibb's performance against key rivals in the ethical pharmaceutical sector.
*Assess the level of generic exposure faced by Bristol-Myers Squibb out to 2013, driven primarily by patent expiry for its lead product Plavix in 2011.
*Analyze BMS's biologics-led growth strategy out to 2013, driven by its existing access to Erbitux and Orencia and new biologic launches also
http://www.companiesandmarkets.com/information.asp?id=5JDA18OJT47860
CONTACT: Mike King, Director, www.companiesandmarkets.com Tel: +44 (0)1933 674 780 Fax: +44 (0)1933 674 780 e-mail: info@companiesandmarkets.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index